Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Starting soon · Early Phase 1

Conditions studied: Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer

In brief

The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.

Key facts

Study ID

NCT07358195

Run by

Massachusetts General Hospital

People needed

3

Starts

2026-07-01

Expected to finish

2029-12-01

Last updated by the study team

2026-01-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Active serious infection
• Participation in other investigational drug use at the time of enrollment
• Positivity for active infection with HIV, HCV, or HBV
• ABO blood group incompatibility in the host-vs-graft direction

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.